TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27812547
Drug: Inhaled sodium
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled sodium nitrite at doses of 45 mg and 90 mg
Study: 27812547
Drug: Inhaled sodium
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled sodium nitrite
Study: 27813195
Drug: D-mannose powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-mannose powder 1.5 grams twice daily for 16 weeks
Study: 27814377
Drug: 7.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 μg of the homologous strain vaccine re-immunized at 6-months
Study: 27814377
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg alum-adjuvanted clade 2, A/Indonesia vaccine re-immunized at 22-months
Study: 27814377
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg alum-adjuvanted A/Vietnam vaccine
Study: 27814709
Drug: Acupoint herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint herbal plaster treatments (4 applications using moxibustion technique)
Study: 27814709
Drug: Acupoint herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint herbal plaster treatments
Study: 27814763
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of delivering three doses of SP
Study: 27815915
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg every other week for 16 weeks
Study: 27816492
Drug: Tremelimumab (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab (3.5 and 10mg/kg i.v.) every 4 weeks for 6 doses, followed by 3-monthly infusions until off-treatment criteria were met.
Study: 27816492
Drug: Tremelimumab in
Normalized name: tremelimumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab in combination with subtotal radiofrequency ablation or chemoablation.
Study: 27816492
Drug: Tremelimumab in
Normalized name: tremelimumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab in combination with tumor ablation.
Study: 27821451
Drug: Auranofin, 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auranofin, 6 mg orally daily for 7 days
Study: 27822376
Drug: Magnetic resonance-guided
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic resonance-guided high-intensity focused ultrasound (HIFU) treatment
Study: 27825292
Drug: Acute spondylolysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute spondylolysis treatment
Study: 27825340
Drug: Nurse-led telecoaching
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led telecoaching programme consisting of 5 monthly telephone sessions of +/- 30 min
Study: 27825636
Drug: Cabozantinib 60
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60 mg orally per day
Study: 27827322
Drug: Adiponectin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adiponectin and thigh subcutaneous adipose tissue in women without PCOS
Study: 27828822
Drug: Fluorescence imaging
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluorescence imaging (FI) using indocyanine green (ICG) at 0.25 mg/kg IV-injected intraoperatively
Study: 27828943
Drug: Selective PI3Kγ
Normalized name: Pi3k.delta.-in-2
DrugBank: Linperlisib (DB17235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective PI3Kγ inhibitor (IPI-549)
Study: 27829430
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to pRBC surface antigens
Study: 27829430
Drug: Opsonizing antibody
Normalized name: Opsonizing antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opsonizing antibody
Study: 27829430
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to merozoite antigens and non-placental-binding IEs
Study: 27829430
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to placental-binding infected erythrocytes
Study: 27830207
Drug: Interactive Binocular
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive Binocular Treatment (I-BiT™) with patching
Study: 27831501
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody (mAb) therapy
Study: 27833752
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CPOT and BPS
Study: 27834750
Drug: Patients deemed
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients deemed too good for intravenous tissue-type plasminogen activator
Study: 27836022
Drug: LVAD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LVAD therapy
Study: 27836716
Drug: Brigatinib 180
Normalized name: brigatinib 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigatinib 180 mg once daily
Study: 27836716
Drug: Brigatinib 90
Normalized name: brigatinib 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigatinib 90 mg once daily
Study: 27836716
Drug: Brigatinib 180
Normalized name: brigatinib 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigatinib 180 mg once daily with a 7 day lead-in at 90 mg
Study: 27836860
Drug: Everolimus as
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus as primary therapy
Study: 27842560
Drug: AposTherapy (biomechanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: AposTherapy (biomechanical treatment)
Study: 27843120
Drug: Panobinostat 20
Normalized name: panobinostat 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat 20 mg in combination with bortezomib, thalidomide, and dexamethasone
Study: 27843136
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m²) as part of high-dose methotrexate-based immuno-chemotherapy
Study: 27843557
Drug: Walnut-included diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut-included diet (56 g, 366 kcal per day)
Study: 27843564
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg/day maintenance dose (MD)
Study: 27843564
Drug: Prasugrel 5
Normalized name: prasugrel 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 5 mg/day maintenance dose (MD)
Study: 27843625
Drug: PRAME immunotherapeutic
Normalized name: PrameGel Reformulated Apr 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRAME immunotherapeutic (recPRAME) with AS15, 20 µg in cohort 1
Study: 27843625
Drug: PRAME immunotherapeutic
Normalized name: PrameGel Reformulated Apr 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRAME immunotherapeutic (recPRAME) with AS15, 100 µg in cohort 2
Study: 27843625
Drug: PRAME immunotherapeutic
Normalized name: PrameGel Reformulated Apr 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRAME immunotherapeutic (recPRAME) with AS15, 500 µg in cohort 3
Study: 27846060
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated chimeric Japanese encephalitis vaccine booster dose
Study: 27846821
Drug: 800 or
Normalized name: Acitak 800 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 or 1600 IU vitamin D3 with calcium (one or two tablets daily) for 10 months
Study: 27846913
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) with cisplatin, 5-fluorouracil, and docetaxel (TPF) plus concurrent chemoradiotherapy (CCRT)
Study: 27847367
Drug: MenB-4C vaccine
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenB-4C vaccine
Study: 27848065
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant (OAC) therapies in patients with significant valvular disease (SVD)
Study: 27848065
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant (OAC) therapies in patients with non-significant valvular disease (NSVD)
Study: 27848182
Drug: Elotuzumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elotuzumab (10 mg/kg, increased to 20 mg/kg if no DLTs), lenalidomide (25 mg orally), dexamethasone (28 mg orally plus 8 mg intravenously on elotuzumab days; 40 mg orally on non-elotuzumab days)
Study: 27852119
Drug: Albiglutide 30
Normalized name: ALBIGLUTIDE 30MG/0.5ML INJ PEN 0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide 30 mg plus a single OAD (sulfonylurea)
Study: 27852119
Drug: Albiglutide 30
Normalized name: ALBIGLUTIDE 30MG/0.5ML INJ PEN 0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide 30 mg plus a single OAD (glinide)
Study: 27852119
Drug: Albiglutide 30
Normalized name: ALBIGLUTIDE 30MG/0.5ML INJ PEN 0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide 30 mg plus a single OAD (other OADs)
Study: 27852119
Drug: Albiglutide (uptitrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide (uptitrated to 50 mg after Week 4)
Study: 27852260
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids for 2 weeks and budesonide/formoterol for 12 weeks
Study: 27852260
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids for 2 weeks
Study: 27852955
Drug: Rx (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rx (oral trimethoprim-sulfamethoxazole or minocycline plus oral rifampin; chlorhexidine mouthwash for 2 weeks; nasal mupirocin and chlorhexidine body wipes for 5 days; environmental decontamination for 21 days)
Study: 27853379
Drug: Platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based chemotherapy (with pemetrexed or gemcitabine)
Study: 27855112
Drug: Caspofungin (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin (standard dose)
Study: 27855624
Drug: Long-term PDE5
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term PDE5 inhibition (PDE5 inhibitors)
Study: 27855624
Drug: Estrogen receptor
Normalized name: Estrogen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen receptor modulation with PDE5 inhibitors
Study: 27855998
Drug: Teduglutide 0.0125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teduglutide 0.0125 mg/kg/d
Study: 27855998
Drug: Teduglutide 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teduglutide 0.025 mg/kg/d
Study: 27856405
Drug: mHealth technology
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth technology (computer tablet)
Study: 27856405
Drug: Home visitor-administered,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home visitor-administered, paper-based method
Study: 27856480
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment (ON)
Study: 27856480
Drug: No pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pharmacological treatment (OFF)
Study: 27856951
Drug: Elevated Lp(a)
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated Lp(a) levels (>30 mg/dL)
Study: 27856951
Drug: Normal Lp(a)
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Lp(a) levels (≤30 mg/dL)
Study: 27857630
Drug: Action Observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Action Observation Therapy (AOT) in addition to conventional physical therapy
Study: 27857630
Drug: Written information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written information in addition to conventional physical therapy
Study: 27860160
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment for 1 week
Study: 27861509
Drug: Azithromycin-Chloroquine (AZCQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azithromycin-Chloroquine (AZCQ) 250/155 mg, single 3-day course
Study: 27863192
Drug: Induction chemotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy, dose-escalated hyperfractionated craniospinal radiotherapy, and maintenance chemotherapy
Study: 27863194
Drug: Pomalidomide 5
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide 5 mg once per day for 21 days per 28-day cycle
Study: 27863197
Drug: Pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 10 mg/kg once every 2 weeks or once every 3 weeks, or 2 mg/kg once every 3 weeks
Study: 27863522
Drug: Prescribed antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed antipsychotic medication regimens (including types, combinations, and Daily Defined Dose equivalent)
Study: 27863522
Drug: Antipsychotic polypharmacy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic polypharmacy and higher doses of antipsychotics
Study: 27864641
Drug: Anodized tapered
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodized tapered implants with a conical connection and integrated platform shifting
Study: 27865764
Drug: rAAV.sFLT-1 gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAAV.sFLT-1 gene therapy
Study: 27865764
Drug: ranibizumab injections
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ranibizumab injections (control)
Study: 28774338
Drug: nab-paclitaxel 125
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 125 mg/m²
Study: 27866695
Drug: Oral formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral formulations of antipsychotics (including risperidone, olanzapine, aripiprazole, zuclopenthixol, fluphenazine, and haloperidol)
Study: 27870734
Drug: Preoperative copeptin
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative copeptin (≥9.6 pmol/L)
Study: 27871319
Drug: PEP02 (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEP02 (irinotecan liposome injection) at 80 mg/m²
Study: 27871319
Drug: PEP02 (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEP02 (irinotecan liposome injection) in combination with 5-FU and LV
Study: 27872037
Drug: Internet-based delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based delivery of 6 evidence-based health promotion programs (sexual health, hearing loss, alcohol use, tobacco use, drug use, nutrition and physical activity)
Study: 27872060
Drug: Bortezomib alone
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib alone (1.3 mg/m2)
Study: 27872070
Drug: Cipargamin 30
Normalized name: Cipargamin
DrugBank: Cipargamin (DB12306)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cipargamin 30 mg
Study: 27872070
Drug: Cipargamin 20
Normalized name: Cipargamin
DrugBank: Cipargamin (DB12306)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cipargamin 20 mg
Study: 27872070
Drug: Cipargamin 10
Normalized name: Cipargamin
DrugBank: Cipargamin (DB12306)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cipargamin 10 mg
Study: 27872070
Drug: Cipargamin 15
Normalized name: Cipargamin
DrugBank: Cipargamin (DB12306)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cipargamin 15 mg
Study: 27872070
Drug: Cipargamin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cipargamin (all doses)
Study: 27872115
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test (OGTT) performed at 18-20 gestational weeks (early OGTT)
Study: 27872115
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test (OGTT) performed at 24-28 gestational weeks (regular OGTT)
Study: 27872130
Drug: Ipatasertib (GDC-0068),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib (GDC-0068), 200 mg daily or more
Study: 27872236
Drug: RO6836191 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO6836191 (single doses)
Study: 27872236
Drug: RO6836191 (repeat-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO6836191 (repeat-dose toxicity studies)
Study: 27875519
Drug: Somatostatin receptor
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin receptor expression measured on circulating tumour cells (CTCs) using CellSearch and immunohistochemistry on matched tissue samples.
Study: 27876675
Drug: Trametinib plus
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametinib plus docetaxel (2.0 mg once daily, 75 mg/m2 docetaxel)
Study: 27878356
Drug: Intravenous triapine
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous triapine (48-96 mg/m) in combination with cisplatin chemotherapy
Study: 27878356
Drug: Intravenous triapine
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous triapine (48-96 mg/m)
Study: 27878474
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of warfarin
Study: 27878567
Drug: Peficitinib 150
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib 150 mg daily for 9 days
Study: 27878567
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg on days 1 and 10
Study: 27878619
Drug: Activated carbon
Normalized name: Activated carbon
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated carbon applied locally into the rectum twice daily for 8 weeks
Study: 27878892
Drug: SIGLEC9 polymorphisms
Normalized name: Murine MAb to polymorphic epithelial mucin, human milk fat globule 1
DrugBank: Pemtumomab (DB18563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIGLEC9 polymorphisms (specifically the G allele of rs2075803 and rs2075803 G/rs2258983 A haplotype)
Study: 27878892
Drug: SIGLEC9 rs2075803
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIGLEC9 rs2075803 G/rs2258983 A haplotype
Study: 27878906
Drug: simeprevir 150
Normalized name: simeprevir 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simeprevir 150 mg, daclatasvir 60 mg and sofosbuvir 400 mg, once daily for 12 weeks
Study: 27879486
Drug: Tenofovir administered
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir administered from week 28 of pregnancy until delivery
Study: 27879972
Drug: REGN2810 (anti-PD-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGN2810 (anti-PD-1 monoclonal antibody)
Study: 27881039
Drug: Fludarabine, cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine, cyclophosphamide, and lenalidomide (starting dose 2.5 mg, maximum tolerated dose 5 mg)
Study: 27881569
Drug: Extended-duration oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-duration oral betrixaban (80 mg once daily for 35-42 days)
Study: 27881569
Drug: Standard-dose subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose subcutaneous enoxaparin (40 mg once daily for 10±4 days)
Study: 27882104
Drug: Mesenchymal stem
Normalized name: Human mesenchymal stem cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stem cell (MSC) infusion derived from human umbilical cord
Study: 27883166
Drug: Low-dose rapamycin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rapamycin (0.5mg, 1.0mg, 2mg daily for 12 weeks)
Study: 27883239
Drug: Omalizumab (individualized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (individualized dosing)
Study: 27883239
Drug: Omalizumab (elevated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (elevated dose)
Study: 27883239
Drug: Omalizumab (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (normal dose)
Study: 27883297
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch (maintenance dose)
Study: 27884140
Drug: Cisplatin (on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (on day 1, every 3 weeks) and cetuximab (on day 1, weekly), in combination with oral valproic acid (VPA) given daily from day -14 with a target serum level of 50-100 μg/ml.
Study: 27884766
Drug: GSK2256294 (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2256294 (18 mg)
Study: 27887632
Drug: Sorafenib (antiangiogenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (antiangiogenic drug)
Study: 27887660
Drug: Co-infusion of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-infusion of haplo-identical donor-derived CD19-directed CAR-T cells and mobilized peripheral blood stem cells (PBSC)
Study: 27887660
Drug: Co-infusion of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-infusion of haplo-identical donor-derived CD19-directed CAR-T cells and mobilized PBSC
Study: 27890073
Drug: Nilotinib 400
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 400 mg twice per day
Study: 27890073
Drug: Imatinib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 600 mg once per day
Study: 27890073
Drug: Nilotinib 400
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 400 mg twice per day (excluding crossover responses)
Study: 27890073
Drug: Imatinib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 600 mg once per day (excluding crossover responses)
Study: 27890471
Drug: Riociguat (0.5-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat (0.5-2.5 mg TID) during a 10-week titration phase and a 14-week maintenance phase
Study: 27890471
Drug: Riociguat (0.5-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat (0.5-2.5 mg TID)
Study: 27890936
Drug: Imatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib treatment cessation
Study: 27891230
Drug: Prucalopride 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 0.02 mg/kg
Study: 27891230
Drug: Prucalopride 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 0.04 mg/kg
Study: 27891230
Drug: Prucalopride 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 0.06 mg/kg